2X QC Reviewer

About the Company

Biovac, founded in 2003, revitalises South Africa’s vaccine manufacturing sector by combining local biotechnological expertise with cutting‑edge production technology and global partnerships. The company produces high‑quality sterile vaccines—including a liquid hexavalent childhood vaccine for Sanofi and a multivalent pneumococcal conjugate vaccine for Pfizer—while supplying over 15 million doses annually to South Africa and neighboring markets under stringent cold‑chain conditions. With in‑house product‑development capabilities, Biovac has successfully out‑licensed proprietary technologies and is developing a novel group B streptococcus vaccine to address rising neonatal sepsis. Supported by a 350‑member skilled workforce and more than R800 million invested in infrastructure, Biovac delivers substantial economic benefits and positions itself as a leading African vaccine manufacturer committed to public‑sector collaboration and quality excellence.

Job Description